In February 2022 the India National Anti-Doping Agency (INADA) reported an anti-doping rule violation against the Athlete Radha Chaudhary after her sample tested positive for the prohibited substance Clomifene.
Following notification a provisional suspension was ordered, yet not accepted by the Athlete. She filed a statement in her defence and she was heard for the Anti-Doping Disciplinary Panel of India (ADDPI).
The Athlete admitted the violation and denied the intentional use of the substance. She asserted that she underwent medical treatment for her condition and had used medication prescribed by her doctor.
INADA rejected the validity of the medical treatment the Athlete underwent. It contended that she had committed an anti-doping rule violation and failed to mention on the Doping Control Form her medication.
The Panel finds that the presence of a prohibited substance had been established in the Athlete's sample and accordingly that she committed an anti-doping rule violation. The Panel determines that she acted negligently with her medication, nor had applied for a TUE
In view of the evidence the Panel deems that the Athlete's diagnosis and treatment of her condition was inadequate. Further the Panel considers that she failed to mention her medication on the Doping Control Form and not had accepted the provisional suspension.
Therefore the Panel decides on 7 July 2023 to impose a 4 year period of ineligibility on the Athlete, starting on the date of the decision.
